Multiple modality treatment of carcinoma cells with Pt(Rh-123)2 plus x-ray plus light.

G. Ara, A. Varshney, Chul S Ha, A. R. Oseroff, T. S. Herman, B. A. Teicher

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A complex of platinum tetrachloride with two molecules of rhodamine-123 (Rh-123), Pt(Rh-123)2, has been reported to act as hypoxic cell radiosensitizer of carcinoma cells in vitro and in vivo. In the present paper we report that Pt(Rh-123)2 photosensitizes human mammary carcinoma (MCF-7) cells and cis-platinum resistant human mammary carcinoma (MCF-7/CP) cells to 400-800 nm light in vitro. The efficiency of photosensitization by Pt(Rh-123)2 was 10 times greater than for Rh-123. Combination therapy using Pt(Rh-123)2 plus x-ray plus light was also much more effective compared to the combination therapy using Rh-123 plus x-ray plus light. After 15 microM of Rh-123 plus x-ray (0-8 Gy) plus light (5 J/cm2) treatment, cell survival curve was parallel to the x-ray cell survival curve with an initial decrease in the surviving fraction corresponding to the drug plus light mediated killing. Cell killing caused by Rh-123 (15 microM) plus x-ray (0-8 Gy) plus light (5 J/cm2) was additive as determined by the product of the surviving fraction after Rh-123 plus light and x-ray. In contrast, for 15 microM of Pt(Rh-123)2 plus x-ray (8 Gy) plus light (5 J/cm2) treatment, whereas additive killing predicts a survival fraction of approximately 0.024, in reality, the combination therapy caused the survival fraction to decrease to 0.0012, implying that the cell killing was enhanced by a factor of 20. Using Pt(Rh-123)2 plus x-ray plus light, supra-additive cell killing was also observed under hypoxic conditions, although compared to normally oxygenated conditions the degree of cytotoxicity was significantly reduced.(ABSTRACT TRUNCATED AT 250 WORDS)

Original languageEnglish (US)
Pages (from-to)561-567
Number of pages7
JournalPhotochemistry and Photobiology
Volume55
Issue number4
StatePublished - Apr 1992
Externally publishedYes

Fingerprint

Rhodamine 123
rhodamine
cancer
Cells
X-Rays
Carcinoma
Light
X rays
x rays
therapy
MCF-7 Cells
Reality Therapy
Cell Survival
platinum
Breast Neoplasms
Photosensitivity Disorders
tetrachlorides
curves
Cytotoxicity
cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Biophysics

Cite this

Ara, G., Varshney, A., Ha, C. S., Oseroff, A. R., Herman, T. S., & Teicher, B. A. (1992). Multiple modality treatment of carcinoma cells with Pt(Rh-123)2 plus x-ray plus light. Photochemistry and Photobiology, 55(4), 561-567.

Multiple modality treatment of carcinoma cells with Pt(Rh-123)2 plus x-ray plus light. / Ara, G.; Varshney, A.; Ha, Chul S; Oseroff, A. R.; Herman, T. S.; Teicher, B. A.

In: Photochemistry and Photobiology, Vol. 55, No. 4, 04.1992, p. 561-567.

Research output: Contribution to journalArticle

Ara, G, Varshney, A, Ha, CS, Oseroff, AR, Herman, TS & Teicher, BA 1992, 'Multiple modality treatment of carcinoma cells with Pt(Rh-123)2 plus x-ray plus light.', Photochemistry and Photobiology, vol. 55, no. 4, pp. 561-567.
Ara, G. ; Varshney, A. ; Ha, Chul S ; Oseroff, A. R. ; Herman, T. S. ; Teicher, B. A. / Multiple modality treatment of carcinoma cells with Pt(Rh-123)2 plus x-ray plus light. In: Photochemistry and Photobiology. 1992 ; Vol. 55, No. 4. pp. 561-567.
@article{ecdab206db6f4f8d8c9564e8df532789,
title = "Multiple modality treatment of carcinoma cells with Pt(Rh-123)2 plus x-ray plus light.",
abstract = "A complex of platinum tetrachloride with two molecules of rhodamine-123 (Rh-123), Pt(Rh-123)2, has been reported to act as hypoxic cell radiosensitizer of carcinoma cells in vitro and in vivo. In the present paper we report that Pt(Rh-123)2 photosensitizes human mammary carcinoma (MCF-7) cells and cis-platinum resistant human mammary carcinoma (MCF-7/CP) cells to 400-800 nm light in vitro. The efficiency of photosensitization by Pt(Rh-123)2 was 10 times greater than for Rh-123. Combination therapy using Pt(Rh-123)2 plus x-ray plus light was also much more effective compared to the combination therapy using Rh-123 plus x-ray plus light. After 15 microM of Rh-123 plus x-ray (0-8 Gy) plus light (5 J/cm2) treatment, cell survival curve was parallel to the x-ray cell survival curve with an initial decrease in the surviving fraction corresponding to the drug plus light mediated killing. Cell killing caused by Rh-123 (15 microM) plus x-ray (0-8 Gy) plus light (5 J/cm2) was additive as determined by the product of the surviving fraction after Rh-123 plus light and x-ray. In contrast, for 15 microM of Pt(Rh-123)2 plus x-ray (8 Gy) plus light (5 J/cm2) treatment, whereas additive killing predicts a survival fraction of approximately 0.024, in reality, the combination therapy caused the survival fraction to decrease to 0.0012, implying that the cell killing was enhanced by a factor of 20. Using Pt(Rh-123)2 plus x-ray plus light, supra-additive cell killing was also observed under hypoxic conditions, although compared to normally oxygenated conditions the degree of cytotoxicity was significantly reduced.(ABSTRACT TRUNCATED AT 250 WORDS)",
author = "G. Ara and A. Varshney and Ha, {Chul S} and Oseroff, {A. R.} and Herman, {T. S.} and Teicher, {B. A.}",
year = "1992",
month = "4",
language = "English (US)",
volume = "55",
pages = "561--567",
journal = "Photochemistry and Photobiology",
issn = "0031-8655",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Multiple modality treatment of carcinoma cells with Pt(Rh-123)2 plus x-ray plus light.

AU - Ara, G.

AU - Varshney, A.

AU - Ha, Chul S

AU - Oseroff, A. R.

AU - Herman, T. S.

AU - Teicher, B. A.

PY - 1992/4

Y1 - 1992/4

N2 - A complex of platinum tetrachloride with two molecules of rhodamine-123 (Rh-123), Pt(Rh-123)2, has been reported to act as hypoxic cell radiosensitizer of carcinoma cells in vitro and in vivo. In the present paper we report that Pt(Rh-123)2 photosensitizes human mammary carcinoma (MCF-7) cells and cis-platinum resistant human mammary carcinoma (MCF-7/CP) cells to 400-800 nm light in vitro. The efficiency of photosensitization by Pt(Rh-123)2 was 10 times greater than for Rh-123. Combination therapy using Pt(Rh-123)2 plus x-ray plus light was also much more effective compared to the combination therapy using Rh-123 plus x-ray plus light. After 15 microM of Rh-123 plus x-ray (0-8 Gy) plus light (5 J/cm2) treatment, cell survival curve was parallel to the x-ray cell survival curve with an initial decrease in the surviving fraction corresponding to the drug plus light mediated killing. Cell killing caused by Rh-123 (15 microM) plus x-ray (0-8 Gy) plus light (5 J/cm2) was additive as determined by the product of the surviving fraction after Rh-123 plus light and x-ray. In contrast, for 15 microM of Pt(Rh-123)2 plus x-ray (8 Gy) plus light (5 J/cm2) treatment, whereas additive killing predicts a survival fraction of approximately 0.024, in reality, the combination therapy caused the survival fraction to decrease to 0.0012, implying that the cell killing was enhanced by a factor of 20. Using Pt(Rh-123)2 plus x-ray plus light, supra-additive cell killing was also observed under hypoxic conditions, although compared to normally oxygenated conditions the degree of cytotoxicity was significantly reduced.(ABSTRACT TRUNCATED AT 250 WORDS)

AB - A complex of platinum tetrachloride with two molecules of rhodamine-123 (Rh-123), Pt(Rh-123)2, has been reported to act as hypoxic cell radiosensitizer of carcinoma cells in vitro and in vivo. In the present paper we report that Pt(Rh-123)2 photosensitizes human mammary carcinoma (MCF-7) cells and cis-platinum resistant human mammary carcinoma (MCF-7/CP) cells to 400-800 nm light in vitro. The efficiency of photosensitization by Pt(Rh-123)2 was 10 times greater than for Rh-123. Combination therapy using Pt(Rh-123)2 plus x-ray plus light was also much more effective compared to the combination therapy using Rh-123 plus x-ray plus light. After 15 microM of Rh-123 plus x-ray (0-8 Gy) plus light (5 J/cm2) treatment, cell survival curve was parallel to the x-ray cell survival curve with an initial decrease in the surviving fraction corresponding to the drug plus light mediated killing. Cell killing caused by Rh-123 (15 microM) plus x-ray (0-8 Gy) plus light (5 J/cm2) was additive as determined by the product of the surviving fraction after Rh-123 plus light and x-ray. In contrast, for 15 microM of Pt(Rh-123)2 plus x-ray (8 Gy) plus light (5 J/cm2) treatment, whereas additive killing predicts a survival fraction of approximately 0.024, in reality, the combination therapy caused the survival fraction to decrease to 0.0012, implying that the cell killing was enhanced by a factor of 20. Using Pt(Rh-123)2 plus x-ray plus light, supra-additive cell killing was also observed under hypoxic conditions, although compared to normally oxygenated conditions the degree of cytotoxicity was significantly reduced.(ABSTRACT TRUNCATED AT 250 WORDS)

UR - http://www.scopus.com/inward/record.url?scp=0026846359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026846359&partnerID=8YFLogxK

M3 - Article

C2 - 1620732

AN - SCOPUS:0026846359

VL - 55

SP - 561

EP - 567

JO - Photochemistry and Photobiology

JF - Photochemistry and Photobiology

SN - 0031-8655

IS - 4

ER -